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Abstract
During early atherogenesis, low density lipoprotein (LDL) induces the accumulation of cholesterol and oxys-
terols in arterial macrophages, and in the subendothelial accumulation of atherogenic lipoproteins in extra-
cellular matrix (ECM), takes place.
Retention of LDL and oxidized LDL (Ox-LDL) to ECM is mediated by the ECM proteoglycans (PGs), which in
the presence of Lipoprotein Lipase (LPL, acting as a bridging element), bind the lipoproteins. The structures of
the ECM proteoglycans, as well as the lipoproteins binding sites for PGs determine the extent of the interac-
tion between ECM PGs and lipoproteins. Following its retention to the ECM, Ox-LDL is taken up by activated
macrophages at enhanced rate, leading to cellular accumulation of cholesterol and oxysterols in arterial wall
macrophages. Moreover, LDL oxidation in the arterial wall can also take place after lipoprotein retention to
ECM PGs. In this case, retained Ox-LDL can be taken up by macrophage after its release from ECM PGs; but
also as a complex of Ox-LDL with ECM PGs. The amount and composition of ECM, produced by all major
cells of the arterial wall (monocyte-derived macrophages, endothelial cells and smooth muscle cells), deter-
mine the extent of lipoproteins cellular uptake. We have demonstrated that under oxidative stress, ECM PGs
secretion from macrophages, binding of Ox-LDL to the ECM and uptake of the retained lipoproteins by
macrophages are all significantly increased. Altogether, these processes contribute to macrophage foam cell
formation and accelerated atherosclerosis.
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Mechanisms involved in
early atherosclerosis
The hypotheses implicated for the mechanisms in-
volved in early atherogenesis include endothelial injury,
lipoprotein modifications (oxidation, aggregation) and
LDL retention [1–4]. However, there is a consensus re-
garding the fact that whatever process triggers the initi-
ation of atherogenesis, it always leads to macrophage
cholesterol accumulation and foam cells formation, the
hallmark of early atherogenesis [1, 5].
Foam cells formation results from complex interac-
tions among cells of the arterial wall (endothelial cells,
smooth muscle cells — SMCs and monocyte-derived
macrophages), arterial lipoproteins (native-LDL, oxi-
dized-LDL and aggregated LDL) and extracellular ma-
trix (ECM) (Fig. 1).
Early atherosclerotic plaque formation begins with
the attachment of blood monocytes to the luminal sur-
face of the endothelium, followed by their subsequent
migration into the subendothelial space [6, 7]. In the
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arterial wall, monocytes differentiate into macrophages
which, under certain conditions such as oxidative stress
[8, 9], accumulate massive amounts of lipoprotein-de-
rived cholesterol and oxysterols and are converted into
foam cells [2, 10, 11]. Oxidized LDL (Ox-LDL) was shown
to be a major contributor to the development of athero-
sclerosis, as it enhances cellular cholesterol accumulation,
as well as inflammatory and thrombotic processes [2, 5,
12, 13]. Extracellular matrix is composed of molecules
secreted by cells of the arterial wall and it was shown to
participate in foam cell formation, mainly by mediating
the retention of atherogenic lipoproteins [4].
Structure and functions
of the extracellular matrix
Extracellular matrix of the atherosclerotic lesion
consists of collagen (Type I, III, IV, V and VI), elastic
fibers (elastin and fibrillin), glycoproteins (fibronectin,
fibrin, thrombospondin, tenascin, osteospontin) and pro-
teoglycans (versican, decorin, biglycan, perlecan and hy-
aluronan) [13, 14].
The extracellular matrix participates in several key
events during the development of the atherosclerotic
lesion which include the following:
1. Cell adhesion: Fibronectin, thrombospondin and
osteopontin are glycoproteins which are elevated in
ECM from atherosclerotic lesions. These glycoproteins
possess cell binding domains that serve as attachment
sites for vascular cells [14].
2. Thrombosis and coagulation: Exposure of the
extracellular matrix during plaque rupture or endothe-
lial injury results in platelet adhesion and activation and
stimulates thrombosis. Fibronectin and thrombospon-
din regulate platelet adhesion and aggregation during the
generation of a thrombus. Moreover, platelets tend to
adhere preferentially to regions of the plaque that are
enriched with type I and type III collagen. Whereas the
fibrous components of the ECM are prothrombotic,
specific glycosaminoglycans of vascular proteoglycans are
considered anti-thrombotic [15].
3. Calcification: Osteopontin is a calcium binding
protein found in atherosclerotic lesions and is mainly
secreted by macrophages [16].
4. Plaque rupture: Plaque fissuring and subsequent
thrombosis often occurs at boundaries between colla-
gen-rich and collagen-poor zones, such as the base of
fibrous caps or near lipid-rich areas, especially in areas
containing interstitial collagens degrading metalloprotei-
nases [17]. Metalloproteinase are synthesiszed by mac-
rophages, smooth muscle cells (SMC) and mast cells,
and are elevated in aneurysmal aortic segments. They
are localized to the regions of the plaque that are most
prone to rupture such as the plaque shoulder, lipid core
or both [18].
5. Cell migration and proliferation: Glycoproteins
from the ECM which are synthesized by SMC interact
with specific cell membrane receptors. Such interactions
regulate the proliferative and migratory behavior of SMC
during colonization of the thrombus or during the de-
velopment of the vascular lesion [13]. Moreover, ECM
also participates in restenosis and increase the expres-
sion of neointimal ECM components (type III collagen,
byglican, hyaluronan and versican) [19].
6. LDL retention: Arterial ECM contribute to the
trapping of LDL in the arterial wall, a phenomenon
called “lipoprotein retention” [4, 13]. Extracellular
matrix proteoglycans were shown to be responsible
for the entrapment of LDL and modified forms of LDL
in the arterial wall [20, 21]. Lipoprotein retention me-
diated by proteoglycans is a major process in arte-
rial ECM-induced foam cell formation. The nature and
the structure of the proteoglycans present in ECM, as
well as the binding sites for ECM proteoglycans in the
lipoprotein molecule determine the level and type of
interaction between the ECM proteoglycans and the
lipoproteins.
Extracellular matrix proteoglycans
synthesis
Proteoglycans (PGs), also known as mucopolysach-
arides, represent a class of protein-carbohydrate com-
pounds. They are characterized by glycosaminoglycans
(GAGs) that are covalently linked to a peptide chain (the
core protein). Proteoglycans from the extracellular
matrix include chondroitin sulfate (CS) linked to a core
protein versican, dermatan sulfate (DS) with a core pro-
tein decorin or byglican, and heparan sulfate (HS) linked
to perlecan core protein [13]. Hyaluronan, which is
a glycosaminoglycan (not PG) is also found in the ECM.
Figure 1. Extracellular matrix and foam cell formation; Foam
cells formation results from the interactions among cells of
the arterial wall (endothelial cells, SMCs and monocyte-
-derived macrophages), lipoproteins (LDL, oxidized LDL and
aggregated LDL) and the extracellular matrix
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There are both spatial and temporal changes in each
of the ECM components during the evolution of the
atherosclerotic plaque. The distribution of proteogly-
cans in the arterial intima varies with the anatomical lo-
cation, during intimal thickening and lesion development
[13, 14]. The proteoglycan layer of the intima becomes
more prominent with physiological intima thickening at
branching points and during early atherogenesis. These
changes are controlled by a coordinate regulation of the
synthesis and turnover of each ECM component by dif-
ferent vascular cells [22]. The development of ECM
during atherogenesis is affected by pro-atherogenic stim-
uli. Predisposing stimuli such as oxidative stress or shear
stress can stimulate synthesis of lipoproteins retentive
molecules such as PGs. These stimuli can also increase
the levels of lipoprotein lipase (LPL), a process which
can change the ECM composition [23].
The regional differences in the distribution of prote-
oglycans during the development of atherosclerotic
plaque, suggest different roles for each of the prote-
oglycans in the atherogenic process. Chondroitin sul-
fate and hyaluronan are both prominent in the intima of
early developing atherosclerotic lesions, whereas der-
matan sulfate with byglican and decorin are found in the
fibrous cap of atherosclerotic regions [24].
The normal intima, and regions prone to lesion de-
velopment are initially rich in large versican-like PGs.
These are the most abundant PGs of the intimal extra-
cellular space and contain chondroitin sulfate as GAGs
[25]. The content of chondroitin sulfate proteoglycans
(CSPGs) increases with lesion progression and eventual-
ly decreases in advanced lesions. The structure of CSPGs
changes with lesion development in humans, and CS-rich
PGs were also shown to be increased with lesions devel-
opment in rabbit atheroma. Versican-like PGs, because
of their abundance and high affinity apolipoprotein B-100
containing lipoproteins, are most likely the main struc-
ture of the intima which interacts with lipoprotein parti-
cles that reach this space [26]. In rabbit models of athero-
sclerosis, the apo B-100 in the intima is colocalized with
CS-rich acellular regions [27]. However, other PGs that
are less abundant than versican can also form complexes
with LDL. Decorin, a small PG, which contains a single
dermatan sulfate chain that is interconnected and organ-
izes collagen I and III fibers in the intima, is a prominent
component of the fibrous cap. Decorin has been shown
to bind LDL as well as Ox-LDL in the presence of LPL.
Byglican is also a small PG with two dermatan sulfate
GAGs present in lesions, and appears to bind LDL [28].
In the abluminal side the large HSPG type perlecan forms
part of the basement membrane that binds the cells to
the proteoglycan layer of the intima.
Extracellular matrix can be produced in vitro by ar-
terial cells, including endothelial cells [29] and smooth
muscle cells [30]. This extracellular matrix is similar in
organization and chemical composition to naturally oc-
curring basal lamina [31]. We have recently demonstrat-
ed that macrophages can also deposit an extracellular
matrix [32]. Macrophages were previously shown to be
able to secrete several components of extracellular
matrix, such as collagen, laminin, fibronectin and prote-
oglycans [33, 34]. Moreover, since macrophages are in-
volved in the formation of the early atherosclerotic le-
sion [2, 6, 7], the secretion of a macrophage derived
ECM could occur already at early stage of atherogene-
sis, and therefore could be crucial for the lipoprotein
retention process.
Retention of native LDL
by extracellular matrix
Extracellular matrix proteoglycans are responsible
for the entrapment of LDL in the arterial wall [4, 20,
23]. This interaction can be a direct one between gly-
cosaminoglycans and apolipoprotein B-100 or it may
involve a bridging molecule such as lipoprotein lipase
(LPL) [31, 35, 36]. Once LDL is trapped in the arterial
wall, which is a relatively antioxidant-poor environment,
it is susceptible to oxidation [37] as well as to aggrega-
tion [38, 39]. Oxidation of retained LDL is thought to
result in its separation from the ECM, followed by its
cellular uptake by arterial macrophages, leading to foam
cell formation [37, 40, 41].
Both heparan sulfate and dermatan sulfate (specifi-
cally decorin), were shown to participate in the reten-
tion of LDL in the subendothelial space [41].
Proteoglycans-lipoproteins complexes that were iso-
lated from fatty streaks or from fibrous plaques of human
aorta, induced cholesteryl ester accumulation in macro-
phages [42]. In addition, complexes of isolated arterial
PGs together with lipoproteins are taken up and degrad-
ed by macrophages at enhanced rates in comparison to
non-bound lipoproteins, and as a consequence, the cells
accumulate large amounts of cholesteryl esters [43].
The interaction of LDL with arterial CSPGs was
found to increase the susceptibility of LDL to copper-
-ion-induced oxidation, as well as to cell-mediated LDL
oxidation. This was demonstrated by lipid peroxides
formation, as well as by the increased anodic electro-
phoretic mobility [37, 44].
Metabolic studies indicate that cells bind and degrade
LDL-PGs complexes by a saturable process with a mod-
erate affinity, and this uptake was shown to be mediat-
ed by specific cell surface binding sites [40, 45]. It was
suggested that macrophages metabolize LDL-PGs com-
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plexes predominantly via a receptor-mediated pathway
that was characterized to be a scavenger receptor [46].
However, LDL modified by its association with isolated
artery wall PGs was shown to be metabolized via the
LDL receptor [40]. The apparent discrepancies between
these two studies can be explained by the different na-
ture of the complexes used in these studies. Hurt et al.
[40] used complexes with a low ratio of PGs to LDL
and the nature of the interaction between the lipopro-
tein and PGs was reversible, compared to the studies
conducted by Viyagopal et al. [46].
Up to eight specific regions in apo B-100 can bind
glycosaminoglycans [47]. Weisgraber & Rall identified two
fragments, residues 3134–3209 and 3356–3367, that bind
to heparin with very high affinity [48]. Camejo et al. con-
firmed these findings and proposed that residues 3147–
–3157 (site A) and residues 3359–3367 (site B) may act
cooperatively in their association with proteoglycans [49].
By analyzing the proteoglycan-binding activity of re-
combinant human LDL isolated from transgenic mice,
the site B (3359–3369) was shown to be the primary
PG-binding site for LDL [50]. Substitution of neutral
amino acids for basic amino acids residues in site B
(3359–3369) abolished both the receptor-binding and
the proteoglycan-binding activities of the recombinant
LDL. Chemical modification of the remaining basic res-
idues caused only a marginal further reduction in prote-
oglycan-binding site of LDL. Although site B was essen-
tial for normal receptor binding and proteoglycan bind-
ing activities, these two activities could be separated in
recombinant LDL with a K3363E mutation. In this latter
LDL, a glutamic acid was inserted into the site B basic
cluster RKR, and this recombinant LDL had normal re-
ceptor-binding but impaired proteoglycans-binding. In
contrast, another mutant R3500Q displayed defective
receptor binding but interacted normally with PGs. Thus,
the PG binding and the receptor binding properties of
LDL can be separated by introducing a single point mu-
tation into the apo B-100.
To investigate the atherogenic potential of the direct
interaction between apo B-100 and arterial proteogly-
cans, transgenic mice that express a PG-binding defec-
tive LDL were produced. These mice were character-
ized by a striking reduction in their atherosclerotic lesion,
in comparison to mice expressing wild type LDL [51].
Retention of oxidized LDL
by extracellular matrix
There has been some controversy regarding the ef-
fect of LDL oxidation on its binding to ECM-PGs [52].
Some studies showed that oxidation of LDL particles
decrease their ability to bind human aortic PGs [53, 54],
whereas in other studies LDL oxidation was shown to
enhance its association with HSPGs anchored to en-
dothelial cells matrix [36, 55, 56]. Oxidation of LDL par-
ticles was shown to decrease their ability to bind to hu-
man aortic proteoglycans [54]. Using several methods
to oxidize LDL, the degree of the binding of the parti-
cles to proteoglycans decreased as the net negative
charge of the lipoprotein particles increased. The in-
crease in the net negative charge of Ox-LDL was ac-
companied with a loss of free lysine residues [54]. Oxi-
dation also decreased LDL association with the suben-
dothelial extracellular matrix. It was thus suggested that
oxidative stress in the vessel wall results in an increased
dissociation of the ECM-bound lipoprotein, which in turn
makes this oxidized LDL more accessible for binding
and uptake by macrophages, leading to cholesterol ac-
cumulation and foam cell formation [52].
However, in another study, oxidation of LDL greatly
enhances its association with lipoprotein lipase anchored
to endothelial cell matrix [55]. Ox-LDL was shown to
bind to ECM-anchored LPL with a 4-fold greater affini-
ty than native LDL, and this interaction was dependent
on the extent of LDL oxidation [55]. The increased af-
finity was caused exclusively by modification of the apo
B-100 and not the lipid moiety of the lipoprotein, and
the apo B-100 arginine residues were shown to play an
important role in Ox-LDL retention.
Mild oxidation of lipoproteins was shown to increase
their affinity for surfaces covered by heparan sulfate and
LPL. Lipoprotein lipase exhibits high affinity for mildly
oxidized LDL [56] and it increased the binding and the
uptake of mildly oxidized LDL, compared to non-oxi-
dized LDL, by THP-1 monocyte-derived macrophages.
Recently, we have shown that macrophage-derived ECM
exhibited an increased binding capacity to oxidized LDL
compared to native LDL, and this binding was mediated
by the ECM heparan sulfate, as well as chondroitin sul-
fate proteoglycans [36]. It is thus possible that LDL ox-
idation can also occur under certain conditions prior to
the retention of the native lipoprotein. Mild oxidation
of LDL increased its binding to chondroitin sulfate,
whereas heavy oxidation reduced LDL binding to CS to
levels lower than that of native LDL binding to CS. Sim-
ilar results were previously reported, showing that mild
oxidation of LDL or of VLDL increased their ability to
bind to heparan sulfate [56]. Chondroitin sulfate prote-
oglycans (CSPGs) secreted by human monocytes-de-
rived macrophages were shown to bind to mildly oxi-
dized LDL but not to extensively oxidized LDL [57],
illustrating that the level of lipoprotein oxidation, as well
as the type of LDL oxidation could be of major impor-
tance in determining PGs interaction with Ox-LDL.
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Role of lipoprotein lipase
in lipoproteins retention
Lipoprotein lipase (LPL) certainly plays a central role
in the retention of lipoproteins in the arterial wall and
the molecule does not need to be catalytically active [4,
23, 35]. We have previously shown [36] that in the ab-
sence of LPL, Ox-LDL, as well as native LDL, were able
to bind to the ECM layer only to a limited extent. Pre-
incubation of ECM layer with LPL however, led to a
substantial increase in the binding of Ox-LDL, as well as
that of native LDL to the matrix. Macrophages isolated
from human atherosclerotic aorta were shown to ex-
press LPL mRNA and to secrete LPL protein [58]. In
addition, a recent study showed that LPL was required
for Ox-LDL binding to proteoglycans (versican and bi-
glycan) from smooth muscle cells derived ECM [59].
Lipoprotein lipase is secreted by macrophages as a
homodimeric form but it rapidly dissociates into inac-
tive monomers, which can be found in the atheroscle-
rotic lesion. It has recently been shown that native LDL
binds only to monomeric LPL whereas Ox-LDL, irre-
spectivly of the type of modification (metal ions, free
radical, oxygenases), binds preferably to the dimeric form
of LPL [60]. The ratio between dimeric and monomeric
LPL in the arterial wall could thus affect the relative re-
tention of Ox-LDL and native LDL to ECM.
Cellular uptake and macrophage foam
cell formation by ECM-retained
lipoproteins
Studies of macrophage lipoproteins uptake are usu-
ally performed by cell incubation with the lipoprotein in
an appropriate medium [61–63]. However, in the arte-
rial wall the lipoprotein may not be in a soluble form,
but rather attached to the ECM.
A recent study analyzed the events occurring during
the interaction of macrophages and matrix-retained ag-
gregated LDL [64]. Using a culture cell model, the ma-
trix-retained lipoprotein was taken up by macrophages,
and this model could mimic the in vivo interaction of arte-
rial wall macrophages with subendothelial lipoproteins.
We have shown that Ox-LDL that was retained by
extracellular matrix can be taken up by activated macro-
phages (Fig. 2). Oxidized LDL is transferred from the ECM
compartment together with its bound PGs to the cellular
compartment. Cellular uptake of the ECM-retained Ox-
-LDL by macrophages can then lead to cholesterol accu-
mulation and foam cell formation, the hallmark of early
atherogenesis [65]. We thus proposed an alternative ap-
proach to study macrophage uptake of oxidized LDL,
different from the classic studies that analyze the uptake
of free, non-bound lipoproteins, by the cells.
Activation of macrophages with PMA is required
however, for the cellular uptake of ECM-retained Ox-
-LDL. PMA-induced macrophage activation can possi-
bly increase the synthesis of high affinity receptors for
Ox-LDL. Macrophage activation through protein kinase
C (PKC) signal transduction pathway can also induce the
secretion of hydrolytic enzymes, growth factors and free
radicals [66]. These secreted substances can then lead
to the release of Ox-LDL-PGs complexes from the
matrix, and its subsequent uptake by the cells.
The cellular uptake of ECM-retained Ox-LDL is thus
accompanied by the uptake of ECM-GAGs [65]. Since
Figure 2. Extracellular matrix-retained Ox-LDL taken up by
macrophages is associated with glycosaminoglycans: Method-
ology approach; A) J-774 A.1 macrophages (5 × 105) were
plated for 5 d in 35 mm wells in medium supplemented with
5% FCS. Then, by addition of Triton × 100 and ammonium
hydroxyde the cell layer was removed leaving the extracellu-
lar matrix layer; B) After extensive washing with PBS the
macrophage derived ECM layer was incubated with 8 µg/ml
of lipoprotein lipase in medium with 3% BSA, for 1 h at 4°C.
After washes with PBS to remove unbound LPL, 125I-Ox-LDL
(or 125I-LDL) were added to the ECM layer for 4 h at 37°C;
C) Then after washing the ECM layer, fresh macrophages
were added to the ECM layer for 18 h at 37°C, in the pres-
ence of 100 mM of PMA; D) Following the incubation, super-
natant medium was removed and analyzed for the determi-
nation of Ox-LDL cellular degradation
A
B
C
D
J-774A.1 Macrophages
ECM
ECM–retained
I-Ox-LDL125
Oxidized-LDL uptake and degradation by macrophages
+Fresh J-774 A.1 Macrophages
+PMA (18 h, 37 C)°
+ LPL (1 h, 4°
°
C)
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+ NH OH
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lipoprotein retention was previously shown to be me-
diated by binding to ECM proteoglycans [20, 21, 23], it
seems that the proteoglycan GAGs are detached from
the core protein and are then taken up by the cells bound
to Ox-LDL. In arterial lesions of atherosclerotic animals,
the presence of PGs-lipoproteins complexes was shown
[27, 67]. These complexes were previously shown to
be taken up at enhanced rate by macrophages and to
cause cellular cholesterol accumulation and foam cell
formation [37, 40, 41].
It can therefore be postulated that oxidation of LDL
may take place in the arterial wall even with no preced-
ing retention of native LDL to ECM. Since LDL oxida-
tion was shown to result in increased association of the
lipoprotein with extracellular matrix [36, 55, 56], LDL
oxidation can possibly trigger the trapping of Ox-LDL in
the arterial wall. Thus, oxidation of LDL can occur also
prior to its retention, unlike the dogma of LDL oxida-
tion only after its retention to ECM (Fig. 3).
Conclusions
The extracellular matrix plays a central role in the
formation of macrophage foam cells during early athero-
genesis. Lipoproteins retention, which is mediated by
ECM proteoglycans (PGs) is probably a major process in
foam cell formation. The nature and the structure of ECM
proteoglycans, as well as the lipoproteins binding sites
for PGs determine the extent of the interaction between
ECM PGs and lipoproteins. Retention of lipoproteins to
ECM proteoglycans was shown for both native LDL an
oxidized LDL (Ox-LDL). This latter ECM-retained Ox-
-LDL is taken up by activated macrophages at enhanced
rate, leading to cellular accumulation of cholesterol and
oxysterols in arterial wall macrophages, a key process in
early atherosclerosis. The content and composition of
ECM produced by all major cells of the arterial wall
(monocyte-derived macrophages, endothelial cells and
smooth muscle cells) determine the extent of lipopro-
teins cellular uptake. Under oxidative stress, ECM secre-
tion, binding of oxidized LDL to ECM and arterial macro-
phage uptake of the retained lipoproteins are all signifi-
cantly increased, contributing to macrophage foam cell
formation and to accelerated atherosclerosis.
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